BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Contract Services

Novo Nordisk's Investment Arm, Novo Holdings, Seals $16.5 Billion Deal to Acquire Catalent in All-Cash Transaction

Catalent, Inc. (NYSE: CTLT), a prominent player in advancing global patient treatment solutions, and Novo Holdings, a holding and investment entity oversee...

February 06, 2024 | News

WuXi Biologics Achieves Milestone with 16,000L Manufacturing Run in Ireland

First manufacturing run successful for MFG7 facility at the Ireland site Largest manufacturing scale to date achieved by combining four 4,000-liter sing...

February 01, 2024 | News

WuXi XDC Partners with Multitude and HySlink for Accelerated ADC Discovery and Development

WuXi XDC will provide a fully integrated, one-stop bioconjugate platform and end-to-end CRDMO services. As WuXi XDC's strategic partner, Multitude Therapeu...

January 31, 2024 | News

WuXi XDC and Celltrion Collaborate on Comprehensive Antibody-Drug Conjugate (ADC) Services

Under the collaboration, Celltrion will delegate WuXi XDC as primary service provider on each of the integrated projects, from process development to GMP m...

January 24, 2024 | News

Kindeva Drug Delivery Acquires Summit Biosciences, a Nasal Drug Development Specialist

The acquisition of Summit enhances Kindeva’s existing drug-delivery capabilities by adding a new drug-delivery platform, further expanding Kindeva&rs...

January 19, 2024 | News

Eurofins CDMO Alphora Completes New Pilot Scale Biologics Facility

The facilities’ offerings include upstream and downstream development, process design, analytical development, GMP QC testing, GMP Cell-Based Assays,...

January 18, 2024 | News

Charles River Streamlines AAV Vector Manufacturing with Rep/Cap Plasmids Launch

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf Rep/Cap plasmid offering, designed to streamline...

January 17, 2024 | News

WuXi Biologics Secures U.S. Patent for WuXiBody™ Antibody Tech

WuXiBodyTM has been widely adopted globally since its launch in 2018. It can effectively break through the CMC barriers for the development of many bi...

January 17, 2024 | News

WuXi Biologics and BioNTech Partner on Monoclonal Antibody Research Agreement

Under the terms of the agreement, WuXi Biologics leverages its proprietary antibody discovery technology platforms (R in CRDMO) to discover two undisclosed...

January 11, 2024 | News

AGC Biologics to Open New Manufacturing Site in Yokohama, Japan

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced plans to construct...

January 05, 2024 | News

WuXi XDC Partners with IntoCell to Boost ADC Discovery and Development

Under the agreement, IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate (OHPASTM) Linker and novel...

January 03, 2024 | News

AGC announces strategic expansion of its Biopharmaceutical CDMO capability in Yokohama, Japan, signaling a new era of innovation and growth

This expansion has been selected by the Japanese Ministry of Economy, Trade and Industry (METI) as part of its "Developing biopharmaceutical manufacturin...

December 26, 2023 | News

Genevoyager (Wuhan) Launches State-of-the-Art CDMO Facility to Propel Gene Therapy Advancements

The newly inaugurated cGMP facility is equipped with its proprietary One-Bac 4.0 System with Sf-RVF® cell line and adheres to the NMPA, FDA and EM...

December 21, 2023 | News

Australian Neuren Phase 2 Trial Reveals Significant Improvements in Phelan-McDermid Syndrome

Highlights: Significant improvement was assessed by both clinicians and caregivers across multiple efficacy measures Improvements were con...

December 19, 2023 | News

Stay Connected